Pamicell Signs Supply Contract for Pharmaceutical Intermediates Worth 1.8 Billion Won
[Asia Economy Reporter Minji Lee] Pamisel, a stem cell therapy research and development company, announced on the 19th that it has signed a supply contract for pharmaceutical intermediate nucleosides with Thermo Fisher Scientific. The contract amount is 1,860,480,000 KRW, which corresponds to 6.56% of recent sales.
Hot Picks Today
!["Buy Before June" - Securities Firms Recommend Stocks Expected to Rise Until 2028 [Weekend Money]](https://cwcontent.asiae.co.kr/asiaresize/93/2026050909404555844_1778287245.jpg)
"Buy Before June" - Securities Firms Recommend Stocks Expected to Rise Until 2028 [Weekend Money]
- From Next Year, "Name Your Price": Tokyo Real Estate Soars to 33-Year High [Mwonilissyu]
- "If It Has Hangul, It Sells Well": Booming Sales Despite Triple the Price... 'Hangul Marketing' Expands Overseas
- "Will It Climb Even Higher?" Target Price Raised to 1.03 Million Won for This Stock [Weekend Money]
- "President Yoon, I Love You"... The Beautiful Woman in Her 20s Who Shouted 'Yoon Again' Was Actually
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
